What the Research Says
A new analysis published in Psychiatric Times this week makes a straightforward but important argument: patients with treatment-resistant depression (TRD) reach remission faster when clinicians actively measure symptoms, adjust doses promptly, and get ahead of side effects rather than waiting for patients to report problems. The piece, "Optimizing the Use of More Efficacious Treatments in Treatment Resistant Depression", frames this around a concept known as measurement-based care—a structured, data-driven approach to clinical monitoring that has been advocated for years but applied inconsistently across psychiatric practice.
TRD affects an estimated 30% of people diagnosed with major depressive disorder—those who fail to respond adequately to at least two antidepressant trials. For this population, the stakes of getting treatment right are high, and the tolerance for slow or passive clinical management is low. The article argues that the availability of more efficacious treatments—including ketamine and its FDA-approved derivative esketamine (Spravato)—makes precise, responsive clinical management more important than ever, not less.
Why This Is Especially Relevant to Ketamine Care
Ketamine and esketamine sit at the top of the efficacy ladder for TRD. Multiple trials have shown that ketamine produces rapid antidepressant effects—often within hours—in patients who have failed conventional treatments. But efficacy in a clinical trial and outcomes in real-world practice are two different things. The Psychiatric Times analysis is essentially a reminder that the drug alone doesn't determine the outcome. How a provider monitors your response, adjusts your protocol, and manages side effects can be just as consequential as the molecule itself.
This is particularly true with ketamine for a few reasons. First, the treatment window is compressed. A standard initial series involves six infusions over two to three weeks, or a similar number of Spravato sessions. There isn't a lot of room to coast. Providers who track your symptoms between sessions and respond to what they're seeing—rather than running everyone through the same rigid protocol—are more likely to find your effective dose before the series ends.
Second, ketamine's side effect profile is distinctive. Dissociation, nausea, elevated blood pressure, and perceptual disturbances are common. These aren't just discomforts—unmanaged side effects are a leading reason patients discontinue treatment before they've had enough exposure to respond. Clinics that prepare patients for what to expect, offer anti-nausea premedication, and monitor vitals throughout sessions are doing exactly what this guidance recommends. Clinics that don't are leaving outcomes to chance.
What Measurement-Based Care Actually Looks Like
Measurement-based care means using validated symptom rating scales at structured intervals to track whether treatment is working. The most common tools in depression care include the PHQ-9, the MADRS (Montgomery–Åsberg Depression Rating Scale), and the QIDS (Quick Inventory of Depressive Symptomatology). These aren't complicated—many are simple self-report questionnaires that take five to ten minutes to complete. But their consistent use creates a feedback loop that informal check-ins simply can't replicate.
For ketamine patients, this kind of tracking matters in concrete ways. A provider reviewing your MADRS scores before each infusion can identify early whether you're on a response trajectory, whether your dose may need to be adjusted, or whether dissociative intensity is interfering with tolerability. Without that data, clinical decisions are based on impression rather than evidence—and in a short treatment window, that gap can cost a patient their best shot at remission.
If you're currently in ketamine treatment or evaluating providers, it's worth asking directly: Which symptom scale do you use? How often do you assess me? What does your dose adjustment protocol look like? What criteria tell you that a session was effective or that the protocol needs to change? These are not unreasonable questions. They're the standard of care this guidance is calling for.
Key Takeaway for Patients
Whether you're receiving IV ketamine infusions or Spravato nasal spray, the quality of clinical monitoring matters as much as the treatment itself. Before starting—or if you're already mid-series and uncertain about your progress—ask your provider how they measure your response, what triggers a dose adjustment, and how they proactively manage common side effects. A good answer should reference specific tools and criteria, not just reassurance.
A Checklist for Evaluating Ketamine Providers
The framework laid out in Psychiatric Times translates into a practical checklist for anyone choosing or assessing a ketamine clinic. Look for providers who offer:
- Structured symptom tracking — Formal depression rating scales completed before and after each session, not just a casual "how are you feeling?"
- A clear dose adjustment protocol — Evidence-based criteria for when and how to modify infusion dose or nasal spray frequency based on response and tolerability
- Proactive side effect management — Pre-session counseling about dissociation, anti-nausea options, vital sign monitoring during infusions, and a structured recovery period
- Defined response criteria — A shared understanding between you and your provider of what improvement looks like, what constitutes remission, and what the maintenance plan is if you respond well
These elements aren't luxuries reserved for academic medical centers. They represent the baseline that good ketamine care should meet. As ketamine continues to move from fringe to mainstream psychiatric practice, patients have more leverage than ever to expect rigor—and to walk away from providers who can't articulate how they measure success.
The Bigger Picture
The Psychiatric Times piece is part of a broader shift in psychiatry toward holding newer, more powerful treatments to a higher operational standard—not just asking "does this drug work?" but "are we using it well?" For ketamine, that's a welcome development. The treatment has accumulated strong evidence for TRD over the past decade. The next frontier isn't a more potent molecule. It's making sure the molecules we already have are deployed with the kind of precision and monitoring that maximizes their benefit for each individual patient.
If you're navigating TRD—whether you've already tried ketamine or are still weighing your options—this guidance is a useful frame. The best outcomes emerge from the combination of an efficacious treatment and a provider who is paying close enough attention to know when it's working, when to push, and when to adjust. That combination is more available than ever. The key is knowing how to find it.
Share